AzTrials
AzTrials

Alcohol DrinkingNCT04893044

Alcohol Misuse Intervention in Active Duty US Navy Personnel

A study testing Video in people with Alcohol Drinking and Alcohol Use Disorder, run by University of New Mexico at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A pilot trial among ship-board US Navy personnel surrounding a holiday weekend tested an evidence-based video on responsible drinking. Service members >18 years were eligible to volunteer if they were aboard during data collection. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Alcohol Drinking, Alcohol Use Disorder
What is being tested?
Video
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteUnited States
Study dates
16 Aug 2019to 10 Oct 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • All members of selected US Navy ship are eligible

Who cannot join

  • Unwillingness to participate

Trial locations and contacts

1 site in 1 country.

United States1 site
  • US Navy

    San Diego, California, 92136

Other trials in United States

About this study

A pilot trial among ship-board US Navy personnel surrounding a holiday weekend tested an evidence-based video on responsible drinking.

Service members >18 years were eligible to volunteer if they were aboard during data collection. Participants were randomized to intervention or control arms, with all given a brief survey before (T1) and after (T2) the weekend. The intervention arm viewed a 3-minute video at T1. A urine specimen collected at T1 and T2 for ethyl glucuronide (EtG) measurement used >100ng/ml for significant alcohol use. Multivariable regression measured odds of detecting EtG at T2, controlling for T1 EtG detectability, age, and alcohol misuse at baseline per AUDIT-C.

86 subjects participated at T1, and 100 at T2, with complete data for 72 (control, n=34; intervention, n=38) who participated in both T1 and T2 were analyzed. Average age was 28 years with 25% and 32% reporting white or black/African-American, 54% married and 84% <E6. At T1, 22% (n=16) and T2, 32% (n=23) had EtG>100ng/ml. At T1, 50% and 55% in control and intervention arms respectively, screened positive for alcohol misuse by AUDIT-C; T1 AUDIT-C screen positivity was significantly associated with detecting EtG>100ng/ml at T1 (p=0.04). Control arm EtG>100ng/ml participants increased 1.7-fold over the weekend, from n=7 at T1 to n=12 at T2; the intervention arm had no increase in EtG>100ng/ml participants, with n=11 at T1 and n=11 at T2.

Read the detailed description

U.S. Navy active duty personnel were recruited to participate in a randomized pilot trial evaluating the efficacy of a 3 minute video intervention designed to promote safer drinking and reduce adverse consequences of alcohol use. All subjects were provided informed consent prior to participation. An incentive of a $5 gift card was provided upon completion of T1, and a $10 gift card provided after completion of T2. Subject participation and data were anonymous; personal identifiers were collected in order to link samples and surveys between timepoint 1 (T1) and timepoint 2 (T2), but after the linking, all identifier data were destroyed. To minimize risk associated with collecting personal identifiers, we did not retain any personal identifiers, to include sex categorization of participants. Subjects completed the T1 survey with only study ID on the form and were then asked to provide a urine sample.

Urine samples were collected in toilet facilities onboard the ship. The collections were not monitored. Urine samples were labelled with the subject ID number and stored at 4 degrees C until they could be shipped. For T1, samples remained refrigerated over the weekend as receiving personnel would not be available during the weekend; at T2, the samples were shipped the following day.

At T1, after providing the urine sample, the intervention subjects watched a 3 minute video, while the control subjects left the area without watching the video.

After the long weekend, subjects were asked to return to the study area, complete a brief survey, and provide a second urine specimen.

The 3 minute video was created for this pilot study. One of the authors with experience in inoculation theory (RJD) guided the content of the video, which was produced, directed and filmed at the New York University Film School.

The T1 surveys collected data on year of birth (as a verification in linking T1 and T2 data in event of linking error), demographic information to include race, relationship status, and pay grade. Additional questions included "have you ever had a drinking problem?", the AUDIT-C questions , and questions regarding if conflicts, accidents or other issues had occurred as a result of alcohol use.

The T2 survey collected year of birth (see above), AUDIT-C questions (modified to reflect data only from the preceding weekend), and the same questions regarding conflicts, accidents or other issues as a result of alcohol use.

Procedure for EtG testing Chemicals and materials Standards of ethyl glucuronide (EtG) and ethyl glucuronide-d5 (EtG-d5) were purchased at concentrations of 1 mg/mL in 1 mL methanol from Cerilliant Corp (Round Rock, TX, US). Liquid chromatography-mass spectrometry (LC-MS) grade methanol, acetonitrile and formic acid, and Sarstedt Inc 10 mL sc tubes 16x100 mm were purchased from Thermo Fisher Scientific (Waltham, MA, US). Nano-Filter vials ® 0.2 µm PES with pre-slit gray cap were from Thomson Instrument Company (Oceanside, CA, US).

Sample preparation: dilution and filtration One hundred µL of urine sample, 300 µL of water and 100 µL of the internal standard EtG-d5 at 0.5 µg/mL were vortex-mixed in a clean Starstedt tube. Two hundred µL of the sample were transferred into the shell vial of the Filter Vial. The plunger with filter was inserted all the way into the shell vial. Twenty µL of the filtered sample were directly injected into the LC-MS/MS.

Calibrators were prepared at concentrations 0.05, 0.1, 0.25, 0.5, 1, 5 and 10 µg/mL, and quality controls at 0.15 and 7.5 µg/mL, using 100 µL of blank urine, 200 µL of water, 100 µL of the corresponding working solution and 100 µL of the internal standard solution.

Instrumental analysis The chromatographic separation was carried out on a Nexera UHPLC system (Shimadzu, Columbia, MD, US). The Nexera UHPLC system consisted of two binary LC-20AD XR high-performance liquid chromatography pumps, online degassing unit (DGU-20A 3R), cooled autosampler (SIL-20A XR) and an oven (CTO-20AC). The column was a Hypercarb column (2.1x 100 mm, 3 µm) from Thermo Fisher Scientific. The mobile phase, 0.1 % formic acid in water (A) and acetonitrile (B), was delivered at a flow rate of 0.3 mL/min. Column temperature was 30C. The gradient began with B at 5% then increasing to 95% in 6 min. B at 95% was held for 0.5 min after which it decreased to 5%, and it was held for 1 min. Total run time was 7.5 min.

The mass spectrometer was a triple quadrupole LCMS-8050 from Shimadzu equipped with electrospray ionization source (ESI). The heating gas and drying gas flows were 15 and 10 L/min, respectively, with a nebulizing gas flow at 2 L/min. The interface temperature was 300°C and the heat block temperature was 400°C. All compounds were analyzed using ESI in negative ionization mode, and two transitions in multiple reaction monitoring (MRM) mode were acquired for each analyte.

Statistical analysis Statistical analyses were performed using Stata version 15.1 (StataCorp, College Station, TX). Descriptive statistics were calculated to characterize participant demographics and by alcohol use at T1 and T2. Fisher's exact tests were used for categorical variables with n<15 in any category and Wilcoxon rank-sum tests for non-normally distributed continuous variables to examine bivariate associations between the groups. All tests were two-sided with significance level of 0.05.

Being tested
Video
Keywords
Military
Medical subject headings
Alcohol Drinking, Alcoholism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VideoBehavioural

    The video was a 3 minutes and based on "inoculation theory" to modify behavior towards moderating the effect of alcohol use as opposed to advising no use at all.

Study groups in NCT04893044
Study groupRoleWhat they receive
ExposureExperimentalThese participants watched a 3 minute long video prior to a long weekend. The intent was to see if watching the video altered their alcohol consumption compared to a group that did not watch the video. Urine alcohol metabolites were measured before and after the weekend.
Receives: Behavioral: Video
ControlNo interventionThese participants did not watch a video, and their urine alcohol metabolites were measures at the same dates as the exposure group above.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Urinary ethyl glucuronide (EtG)

    Alcohol metabolite

    Measured: 3 days

Secondary outcomes (1)
  1. Alcohol Use Disorders Identification Test - Consumption (AUDIT-C) score

    Measurement of self-reported alcohol consumption. The AUDIT-C score is scored on a scale from 0-12. The higher the AUDIT-C score is, the more likely it is to indicate a alcohol use disorder. In males, a score of 4 or higher is a positive screen. In women, a score of 3 or higher represents a positive screen. In this trial, we did not collect male/female data and used a cutoff of 4 for all participants.

    Measured: 3 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 May 2021
  2. Study start16 Aug 2019
  3. Primary completion3 Sep 2019
  4. Study completion10 Oct 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized pilot trial of video intervention
Masking
None (open label)
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04893044
Sponsor's protocol ID
190366
Status last verified
May 2021
First submitted
27 Apr 2021
Last updated
19 May 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • McDonell MG, Skalisky J, Leickly E, McPherson S, Battalio S, Nepom JR, Srebnik D, Roll J, Ries RK. Using ethyl glucuronide in urine to detect light and heavy drinking in alcohol dependent outpatients. Drug Alcohol Depend. 2015 Dec 1;157:184-7. doi: 10.1016/j.drugalcdep.2015.10.004. Epub 2015 Oct 9.

    PubMed 26475403

Questions about this trial

What is this clinical trial studying?

A study testing Video in people with Alcohol Drinking and Alcohol Use Disorder, run by University of New Mexico at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 May 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Urinary ethyl glucuronide (EtG) (time frame: 3 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04893044, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in